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Rare pulmonary diseases: A path to the futureIn their professional lives, physicians involved in respiratory
medicine may occasionally follow pulmonary disorders matching
the definition of a rare disease. However, because of the rarity of
these disorders the physician’s experience in the field is usually
limited to a few cases. Presented in this supplement of Respiratory
Medicine are the proceedings of the Third International Congress
on Rare Pulmonary Diseases and Orphan Drugs in Respiratory
Medicine, held in Milan on 20e21 March 2009. This congress follows
two similar meetings, both held in Milan, the first in February 20051
and the second in February 2007.
Like the 2005 and 2007 meetings the conference reported
here focused on pathogenetic, clinical and therapeutic advances
in the field of rare lung diseases. Topics presented over the 2-
day conference included basic scientific data, genetic projects,
molecular advances and other findings that have contributed to
increase the therapeutic possibilities in patients suffering from
these diseases. Valuable contacts have been generated between
pulmonologists, internists and physicians involved in imaging,
pathology and molecular biology, who have collegially discussed
developments that have emerged in the last 2 years.
The conference reports that have been selected to be published
in this issue begin with the contribution of Sitbon, who reviews
current strategies in the management of pulmonary arterial
hypertension. Humbert discusses an uncommon form of pulmonary
arterial hypertension, pulmonary veno-occlusive disease (PVOD),
and provides an outstanding overview of the clinical and thera-
peutic implications of this rare disease.
Three reports on the topic of idiopathic pulmonary fibrosis were
selected by the editors of this issue. In the first, Cavazza reviews
recent data that have strengthened the role of the pathologist in
this disease, while Caminati gives an update on the clinical
management of these patients. In the third report, Pesci provides
data on his valuable experience in the controversial role of bron-
choalveolar lavage in idiopathic pulmonary fibrosis.
The problem of clinical trials and registries in rare diseases is
considered in the report by Luisetti, who presents and discusses the
international experience with alpha1-antitrypsin deficiency ach-
ieved by the Alpha One International Registry, and national expe-
rience obtained with a large series of patients with pulmonary
alveolar proteinosis. The role of bronchoalveolar lavage and
transbronchial biopsy in the diagnosis of cystic lung diseases is
reviewed by Torre in an interesting overview on this topic that
suggests a number of considerations to the reader.
Various clinical aspects of interstitial lung disease in systemic
sclerosis, and different therapeutic options for the severe restrictive
lung disease that complicates this disease, are extensively reviewed
by Mouthon in an outstanding report. Agostini discusses the0954-6111/$ - see front matter ª 2010 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2010.03.011controversial role of stem cell transplantation in the clinical
management of rare lung diseases; regenerativemedicine is expected
to be a major challenge for the future in respiratory medicine and
various sources of stem cells may be used in different disorders.
In his report Johnson describes the development of guidelines
for lymphangioleiomyomatosis by the European Respiratory Society
and discusses how these guidelines can help the standardization of
diagnostic criteria in this disease, thus improving clinical care and
facilitating research and clinical trials. Moss, taking advantage of
his enormous experience in the field of lymphangioleiomyomatosis,
addresses encouraging new developments in the treatment of this
rare disease.
We hope that the reader taking a look at the reports included
in this issue will receive an impression of the scope of the
discussions that were generated by the data presented during the
various sessions of the congress. Because of the rapidly evolving
field, we plan a fourth international update within the next 2
years.
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